CTOs on the Move

Stephen L. LaFrance Pharmacy d/b/a USA Drug

www.usadrug.com

 
Stephen L. LaFrance, a certified pharmacist, founded the USA Drug family in February 1968. The retail drug store chain now boasts over 110 retail outlets in Tennessee, Mississippi, Missouri, and Arkansas, branded as USA Drug, Super D Drugs and Ike's Deep
  • Number of Employees: 5K-10K
  • Annual Revenue: $500M-1 Billion
  • www.usadrug.com
  • 2100 Brookwood Dr
    Little Rock, AR USA 72202
  • Phone: 501.296.3300

Executives

Name Title Contact Details

Similar Companies

Alliance for Health Care Reform

Alliance for Health Care Reform is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cayce's Pharmacy

Cayce's Pharmacy is a Hopkinsville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Premise Health

Premise Health is here to change the way people see and experience healthcare. We help organizations take healthcare farther – by bringing it closer than ever. We’ve created a worksite health model that achieves better patient engagement, and delivers higher-value programs that sustainably improve health outcomes to worksite and distributed workforces. For employers, this means finally controlling costs – while delivering a leading-edge health benefit that actually benefits health. On behalf of 220+ clients, Premise Health operates over 500 onsite health centers, pharmacies, and fitness centers in 46 states and 2 U.S. territories.

HMC HealthWorks

Say goodbye to a blanket approach to healthcare. We personalize each plan sponsor`s needs toward improving the health and quality of life of participants. The result? Reduced healthcare spend and a healthier population. HMC`s 40 years of clinically-based protocols produces an impact that engages, empowers and delivers.

Envisia Therapeutics

Envisia Therapeutics, formed by Liquidia Technologies in 2013, is a privately held biotechnology company focused on the development of novel ocular therapies. Envisia is leveraging the unique and powerful properties of the PRINT® platform to develop therapies for a variety of ocular conditions, the most advanced of which is ENV515, for the treatment of glaucoma. ENV515 is a novel extended-release formulation of a prostaglandin analogue formulation. It has the potential to significantly limit disease progression and vision loss through improved product performance and patient compliance. Envisia is located in Research Triangle Park, North Carolina.